Business Wire

EQ-3

2.8.2016 10:02:00 CEST | Business Wire | Press release

Share
eQ-3 is Europe’s Number One in Smart Home

According to the renowned market research company Berg Insight, eQ-3 is the European market leader in smart home for the third time in a row. The company jumps ahead with a market share of 35 percent in installed whole home solutions: About 285,000 households in Europe already use whole home solutions from eQ-3. With regard to smart thermostats, there are over 560,000 households already. In total eQ-3 has shipped more than 18 million wireless home control devices.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160802005208/en/

The market research company Berg Insight confirms the company located in Leer, Germany, as market leader in its fourth edition of the “Smart Homes and Home Automation” study. Whole home systems by eQ-3 are already installed in around 285,000 households in Europe today. These include more than six million devices based on the Homematic product line as well as the next smart home generation Homematic IP and major OEM solutions such as RWE smart home. The company has recorded continuous growth over many years in the smart home area, largely thanks to the product line Homematic introduced almost ten years ago. In the last three years, Homematic growth exceeded 75 percent per year, even with the already large installed base. According to Berg Insight, Homematic has three times more installed whole home systems in the consumer segment than all KNX manufacturers together.

The same positive trend becomes apparent when looking at the smart thermostats sector: Over 560,000 households in Europe use smart thermostats from eQ-3 already today, representing a market share of 41 percent. According to Berg Insight, the heating control system MAX! is used in 320,000 households.

In contrast to other smart thermostat solutions, eQ-3 solutions such as Homematic IP, Homematic, and MAX! provide heating control not only for the entire home, but on a room-by-room basis. Therefore, the energy is controlled based on the actual usage of rooms and associated need for heating rooms individually. This results in significantly increased energy savings. Furthermore, while other solutions typically consist of a boiler switch, a thermostat, and a gateway only, the eQ-3 solutions additionally include radiator thermostats, wall thermostats, and window sensors and other devices. When considering that a typical eQ-3 heating solution has eight to nine versus two to three devices, the European market share of eQ-3 based on the number of individual devices would be even above 70 percent.

Another major difference to other smart heating solutions is that eQ-3 provides a smooth extension path to full smart home solutions today, seamlessly adding security and alarm, light and shade, access control and many other applications for mass consumer deployment. The eQ-3 smart home products are marketed under the Homematic IP, Homematic, and MAX! brands through a wide variety of channels, including specialty retailers, Amazon and many online stores, large CE retailers, DIY, and installers that are served by our own field sales force together with the leading electrical wholesaler Sonepar. Additionally, eQ-3 is the technology and product provider behind smart home offerings from RWE, Deutsche Telekom and many other OEMs. With Homematic IP and an earlier OEM solution, eQ-3 is the pioneer in delivering an all-IPv6 smart home solution. Further strengths of Homematic IP are its ease-of-use, confirmed best-in-class security, and a leading position in data privacy thanks to a free, anonymously operated cloud service.

Homematic IP by eQ-3

About eQ-3:

eQ-3 is one of the leading innovation and technology companies for home control and consumer electronics. With more than 200 different types of products, eQ-3 today provides the largest product portfolio in the industry and has placed more than 18 million wireless solutions in more than 600,000 households on the market. This makes eQ-3 the European market leader in smart home technology based on the number of whole home solutions and electronic radiator thermostats installed. Homematic is the leading smart home platform with more than 80 devices and open communication interfaces. Homematic IP, the next generation of Homematic, is based on the Internet standard IPv6 as open platform and fully compatible with the devices of the Homematic family. The products are designed and developed at the headquarters in Leer, Germany. The final manufacturing takes place in the own production plant in South China. The ELV/eQ-3 group has been family owned since its foundation. The eQ-3 group was founded in 2007 as a spin-off from the ELV Elektronik AG, existing since 1978. Further information: www.eQ-3.de , www.HomeMatic.com , www.homematic-ip.com .

Contact:

Press contact:
Sinje Salamon
eQ-3 AG
Marketing Manager
+49 (491) 6008 - 626
sinje.salamon@eq-3.de
or
PR agency:
Benjamin Kolthoff
P.U.N.K.T. Gesellschaft für Public
Relations mbH
+49 (40) 85 37 60 - 29
bkolthoff@punkt-pr.de

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye